Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | K111N |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA K111N lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). K111N results in increased phosphorylation of Akt, activation of downstream signaling, increased cell proliferation and migration, and is transforming in cell culture (PMID: 17376864, PMID: 29533785, PMID: 34779417). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA K111N |
Transcript | NM_006218.4 |
gDNA | chr3:g.179199158G>C |
cDNA | c.333G>C |
Protein | p.K111N |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713658 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179199158G>C | c.333G>C | p.K111N | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA K111N | estrogen-receptor positive breast cancer | sensitive | AZD8835 | Preclinical | Actionable | In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307). | 26839307 |
PIK3CA K111N | breast cancer | sensitive | BAY1125976 | Preclinical - Cell culture | Actionable | In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769). | 27699769 |
PIK3CA K111N | breast cancer | sensitive | Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to Miransertib (ARQ092) in culture, demonstrating inhibition of cell growth (PMID: 26469692). | 26469692 |
PIK3CA K111N | breast cancer | sensitive | Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, Miransertib (ARQ092) treatment induced cell death and inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | ARQ 751 | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). | 26469692 |
PIK3CA K111N | breast cancer | sensitive | ARQ 751 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 751 treatment did not increase cell death but inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | DHM25 | Preclinical - Cell culture | Actionable | In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138). | 26237138 |
PIK3CA K111N | breast cancer | sensitive | Borussertib | Preclinical - Cell culture | Actionable | In a preclinical study, borussertib inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 30858154). | 30858154 |
PIK3CA K111N | breast cancer | sensitive | MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, MK2206 treatment increased cell death and inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | predicted - sensitive | GSK690693 | Preclinical - Cell culture | Actionable | In a preclinical study, GSK690693 treatment did not increase cell death but inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | predicted - sensitive | Ipatasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Ipatasertib (GDC-0068) treatment did not increase cell death but inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | AZD0156 + Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, AZD0156 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | KU-57788 + Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, KU-57788 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | GSK2334470 + Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, GSK2334470 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | Miransertib + OSU-T315 | Preclinical - Cell culture | Actionable | In a preclinical study, OSU-T315 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | Ipatasertib + OSU-T315 | Preclinical - Cell culture | Actionable | In a preclinical study, OSU-T315 and Ipatasertib (GDC0068) combination treatment increased cell death compared to Ipatasertib (GDC0068) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | MEN1611 | Preclinical - Cell culture | Actionable | In a preclinical study, MEN1611 (CH5132799) inhibited viability in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 36913051). | 36913051 |